Searchable abstracts of presentations at key conferences in endocrinology

ea0009p201 | Clinical | BES2005

Controversial issues in the management of hypercalcaemia in a young patient

Varughese G , Roy|#Chowdhury S , Barton D

We report the case of a 41-year-old woman who was under investigation for deranged liver function tests following an insurance medical when she also serendipitously was found to have hypercalcaemia - 2.70 millimols per litre (Reference range 2.45-2.65 millimols per litre). She was completely asymptomatic and on no medication. She had an elevated Parathyroid hormone level of 11.6 picomols per litre (Reference range 0.9-8.0 picomols per litre), consistent with primary hyperparat...

ea0019p195 | Growth and development | SFEBES2009

Delayed puberty: an occult systemic cause

Manjunatha RS , Varughese G , Varadhan L , Clayton RN

We report a 17-year-old male who presented with symptoms of absent secondary sexual characteristics, decreased appetite and infrequent non-specific abdominal pain. He had no complaints of headache, altered sense of smell or colour blindness. His other siblings had normal growth.On examination, he had normal male body habitus, height (157 cm), no gynaecomastia, axillary and beard hair (tanner stage 1) pubic hair (tanner stage 2), testes (12 ml bilaterally...

ea0031p54 | Clinical biochemistry | SFEBES2013

An audit on management of hyponatraemia in hospitalised patients

Katreddy V M R , Nayak A U , Varughese G I , Clayton R N

Background: Amongst hospitalised patients, hyponatraemia is the commonest electrolyte abnormality with reported prevalence of about 25%. Its association with mortality, morbidity and increased length of stay is well recognised, including adverse fracture risk and falls with mild hyponatraemia in elderly. We audited the management of hyponatraemia in inpatients in a University hospital setting.Methods: Over a 3-month period, amongst all in-patients, we id...

ea0009p194 | Clinical | BES2005

Challenges of treating hyperthyroidism

Roy|#Chowdhury S , Varughese G , Redford D , West T , Barton D

We report the case of a 34 year old woman with recurrent hyperthyroid Grave's disease. She was initially found to be thyrotoxic in July 1996. Treatment was commenced with carbimazole, of which she received 12 months in a titration regimen. She relapsed in October 1999, six months following the delivery of her first child, and was restarted on carbimazole, remaining euthyroid on a dose of 10mg. She conceived again in May 2002 (whilst on carbimazole) and treatment was continued ...